1.68
+0.12(+7.69%)
Currency In USD
Address
1030 Massachusetts Avenue
Cambridge, MA 02138
United States of America
Phone
617 952 0555
Website
Sector
Healthcare
Industry
Biotechnology
Employees
45
First IPO Date
April 30, 2021
| Name | Title | Pay | Year Born |
| Dr. Daniel J. Hicklin Ph.D. | Founder, Chief Executive Officer, President, Secretary & Director | 928,264 | 1964 |
| Dr. Chulani Karunatilake Ph.D. | Chief Technology Officer | 343,431 | 1960 |
| Mr. Timothy W. Trost CPA | Chief Financial Officer, Treasurer & Assistant Secretary | 662,989 | 1958 |
| Dr. Randi Isaacs M.D. | Chief Medical Officer | 702,426 | 1956 |
| Dr. William Winston Ph.D. | Senior Vice President of Research | 0 | N/A |
| Ms. Ellen A. Lubman M.B.A. | Chief Business Officer | 0 | 1976 |
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.